Log in

NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Forecast & News

$4.28
-0.02 (-0.47 %)
(As of 03/30/2020 06:00 AM ET)
Today's Range
$3.85
Now: $4.28
$4.32
50-Day Range
$0.52
MA: $2.96
$5.32
52-Week Range
$2.23
Now: $4.28
$18.50
Volume282,950 shs
Average Volume248,777 shs
Market Capitalization$68.82 million
P/E RatioN/A
Dividend YieldN/A
Beta0.68
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Read More
AVEO Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.80 million
Cash Flow$0.58 per share
Book Value$0.92 per share

Profitability

Net Income$9.39 million

Miscellaneous

Employees17
Market Cap$68.82 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.


AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

How has AVEO Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AVEO stock has increased by 22.6% and is now trading at $4.28. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AVEO Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AVEO Pharmaceuticals.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for AVEO Pharmaceuticals.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its earnings results on Monday, March, 16th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.31. The biopharmaceutical company had revenue of $0.76 million for the quarter, compared to analysts' expectations of $2.10 million. AVEO Pharmaceuticals had a return on equity of 225.40% and a net margin of 32.60%. View AVEO Pharmaceuticals' earnings history.

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

AVEO Pharmaceuticals shares reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

2 equities research analysts have issued twelve-month price targets for AVEO Pharmaceuticals' shares. Their forecasts range from $4.00 to $20.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 180.4% from the stock's current price. View analysts' price targets for AVEO Pharmaceuticals.

What are Wall Street analysts saying about AVEO Pharmaceuticals stock?

Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AVEO got a huge boost from the approval for Fotivda in Europe for the first-line treatment of advanced renal cell carcinoma. However, it faced a major setback when it had to delay the new drug application filling for Fotivda in the United States. In September 2019, AVEO announced updated data from the second prespecified analysis of overall survival from the phase III study on Fotivda. The results included an OS hazard ratio of less than one, favoring Fotivda. Failure to receive regulatory approvals or termination of any deal would significantly hurt the stock in future. AVEO receives royalties from Fotivda sales in certain European countries. This is another revenue driver. Shares have underperformed the industry in the past year. Estimates looks stable ahead of Q4 earnings. AVEO has a mixed record earnings surprises in recent quarters." (2/21/2020)
  • 2. HC Wainwright analysts commented, "We raise our rating on AVEO to and increase our 12-month price target to $1.75 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030, assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $393M for the products and add in pro forma net cash and cash equivalents of $65.2M to arrive at a 12-month price target of $1.75 per share. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (9/11/2019)

Has AVEO Pharmaceuticals been receiving favorable news coverage?

Headlines about AVEO stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 1,503,500 shares, a decline of 7.8% from the February 27th total of 1,630,000 shares. Based on an average daily trading volume, of 188,800 shares, the days-to-cover ratio is presently 8.0 days. Approximately 11.2% of the shares of the stock are sold short. View AVEO Pharmaceuticals' Current Options Chain.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Advanced Micro Devices (AMD), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Novavax (NVAX), Alibaba Group (BABA), Opko Health (OPK), Bellicum Pharmaceuticals (BLCM) and Canopy Growth (CGC).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
  • Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 59)
  • Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Jacobs Levy Equity Management Inc. (0.90%), Geode Capital Management LLC (0.61%), Marshall Wace LLP (0.18%), Virtu Financial LLC (0.14%) and Goldman Sachs Group Inc. (0.03%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View institutional ownership trends for AVEO Pharmaceuticals.

Which major investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and Goldman Sachs Group Inc.. View insider buying and selling activity for AVEO Pharmaceuticals.

Which major investors are buying AVEO Pharmaceuticals stock?

AVEO stock was purchased by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Marshall Wace LLP, and Virtu Financial LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini, and Ravi Viswanathan. View insider buying and selling activity for AVEO Pharmaceuticals.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $4.28.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $68.82 million and generates $28.80 million in revenue each year. The biopharmaceutical company earns $9.39 million in net income (profit) each year or $0.61 on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe. View additional information about AVEO Pharmaceuticals.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is http://www.aveooncology.com/.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  355 (Vote Underperform)
Total Votes:  731
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: What is a support level?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel